AGP Picks
View all

Vanuatu Health Times
Provided by AGP

Vanuatu Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

November 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30

Press releases published on November 10, 2026

René Goehrum Files Early Warning Report for Historical Ownership Positions
Nov. 10, 2026

René Goehrum Files Early Warning Report for Historical Ownership Positions

Indeterminate GlobeNewswire
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
Nov. 10, 2026

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

Indeterminate GlobeNewswire
PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology
Nov. 10, 2026

PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology

Indeterminate GlobeNewswire
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Nov. 10, 2026

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Indeterminate GlobeNewswire
Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva
Nov. 10, 2026

Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva

Indeterminate GlobeNewswire
Harvard Bioscience Announces Third Quarter 2026 Financial Results
Nov. 10, 2026

Harvard Bioscience Announces Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Nov. 10, 2026

Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease

Indeterminate GlobeNewswire
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
Nov. 10, 2026

Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption

Indeterminate GlobeNewswire
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Nov. 10, 2026

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Indeterminate GlobeNewswire
LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov. 10, 2026

LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
Nov. 10, 2026

City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease

Indeterminate GlobeNewswire
Kailera Therapeutics to Present at ObesityWeek 2026
Nov. 10, 2026

Kailera Therapeutics to Present at ObesityWeek 2026

Indeterminate GlobeNewswire
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nov. 10, 2026

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov. 10, 2026

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
Nov. 10, 2026

Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
Nov. 10, 2026

Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026

Indeterminate GlobeNewswire
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Nov. 10, 2026

Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

Indeterminate GlobeNewswire
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Nov. 10, 2026

Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN

Indeterminate GlobeNewswire
PridCor Therapeutics Announces First Patient Enrolled in Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID
Nov. 10, 2026

PridCor Therapeutics Announces First Patient Enrolled in Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID

Indeterminate GlobeNewswire
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
Nov. 10, 2026

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Vanuatu Health Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.